Assembly biosciences and beigene announce license and collaboration agreement in china

Assembly biosciences and beigene announce license and collaboration agreement in china for assembly’s portfolio of three clinical-stage core inhibitors for chronic hepatitis b infection.assembly biosciences - granted beigene rights to develop, commercialize abi-h0731, abi-h2158 and abi-h3733 in china, hong kong, macau, and taiwan.assembly biosciences inc - assembly will receive $40 million cash and is eligible to receive up to about $500 million in potential development.assembly biosciences inc - beigene will contribute initial funding for clinical development in china.assembly biosciences inc - after initial funding, development costs for territory will be shared equally by parties.assembly biosciences - currently projects its $249 million in cash at march 31, 2020, will extend its funding of operations into h2 of 2022.
ASMB Ratings Summary
ASMB Quant Ranking